279,490 Shares in AstraZeneca PLC $AZNCF Purchased by Cidel Asset Management Inc.

Cidel Asset Management Inc. bought a new stake in shares of AstraZeneca PLC (OTCMKTS:AZNCF) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 279,490 shares of the company’s stock, valued at approximately $55,095,000. AstraZeneca accounts for about 3.0% of Cidel Asset Management Inc.’s holdings, making the stock its 3rd largest holding.

Other institutional investors have also added to or reduced their stakes in the company. Seven Mile Advisory purchased a new stake in AstraZeneca in the fourth quarter worth about $738,000. Town & Country Bank & Trust CO dba First Bankers Trust CO purchased a new position in shares of AstraZeneca in the 1st quarter valued at approximately $1,351,000. L & S Advisors Inc bought a new stake in shares of AstraZeneca during the fourth quarter valued at approximately $14,863,000. Monetary Management Group Inc. bought a new stake in shares of AstraZeneca during the fourth quarter valued at approximately $1,097,000. Finally, Oarsman Capital Inc. purchased a new stake in AstraZeneca in the fourth quarter worth $5,027,000. 40.87% of the stock is currently owned by institutional investors.

AstraZeneca Stock Performance

AZNCF opened at $187.10 on Wednesday. The stock has a fifty day simple moving average of $187.10 and a two-hundred day simple moving average of $186.15. AstraZeneca PLC has a 12-month low of $122.26 and a 12-month high of $195.00.

AstraZeneca Company Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.